CYTR News and Press, CytRx Corporation From 06/18/21

JHVEPhoto/iStock Editorial via Getty Images Danish biotech Orphazyme ([[ORPH]] -43.0%) has extended the pre-market losses after the FDA decision not to grant the approval for Arimoclomol the company’s experimental therapy for rare genetic disease Niemann-Pick Disease Type C ((NPC)). Cy...

AMC Stock Has Shown Traders Why Penny Stocks Are So Strong Penny stocks are one of the highest risk types of assets you can buy in the stock market. One minute you’re looking at a 200% windfall, the next, you might’ve lost your entire position. The crazy part is that this ...

CalypsoArt/iStock via Getty Images Shares of Orphazyme (ORPH) have suddenly shot up 95% in afternoon trading on the eve of an expected FDA decision on its application for Arimoclomol for the treatment of Niemann-Pick Disease Type C ("NPC"). Trading in the stock was already briefly h...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Satu...

AndrewJohnson/E+ via Getty Images After over a fourfold rise value yesterday, Orphazyme ([[ORPH]] -44.3%) has lost more than a third so far in morning hours. Issuing a clarification, the company said that it was not aware of any reason that caused such extreme volatility in price and vol...

Canberk Sezer/iStock via Getty Images Orphazyme ([[ORPH]] +984.1%) and CytRx ([[CYTR]] +73.5%) have reached their historical high as the companies await the FDA decision on Arimoclomol in the treatment of Niemann-Pick Disease Type C ((NPC)), a rare genetic disease. The experimental treatment ...

CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx’s most recent advanced drug conjugate, aldoxorubicin, is an improved version of ...

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, Chairman and Chief Exe...

CytRx (CYTR): Q1 Net loss of $1.3M.Cash on hand of approximately $9.3 million, which management believes is sufficient to fund ongoing operations for the foreseeable future.Press Release For further details see: CytRx reports Q1 results

Continues Focusing on Near-Term Revenue Opportunities Linked to Orphazyme’s Potential Regulatory Approvals for Arimoclomol in the Treatment of Niemann-Pick Disease Type C CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a spec...